Affiliations: [a] Department of Neurology, Chung-Ang University College of Medicine, Seoul, Republic of Korea
| [b] Research and Development, PeopleBio Inc., Gyeonggi-do, Republic of Korea
| [c] Department of Neurology, Seoul National University College of Medicine & Neurocognitive Behavior Center, Seoul National University Bundang Hospital, Gyeonggi-do, Republic of Korea
| [d] Department of Neurology, Veterans Health Service Medical Center, Seoul, Republic of Korea
| [e] Department of Laboratory Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea
| [f] Department of Bionanotechnology, Gachon University, Gyeonggi-do, Republic of Korea
Correspondence:
[*]
Correspondence to: SangYun Kim, Department of Neurology, Seoul National University College of Medicine & Neurocognitive Behavior Center, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu,
Seongnam-si, Gyeonggi-do, 463-707 Republic of Korea. Tel.: +82 31 787 7462; E-mail: neuroksy@snu.ac.kr.
Abstract: Background:Oligomeric amyloid-β (Aβ) is one of the major contributors to the pathomechanism of Alzheimer’s disease (AD); Aβ oligomerization in plasma can be measured using a Multimer Detection System-Oligomeric Aβ (MDS-OAβ) after incubation with spiked synthetic Aβ. Objective:We evaluated the clinical sensitivity and specificity of the MDS-OAβ values for prediction of AD. Methods:The MDS-OAβ values measured using inBlood™ OAβ test in heparin-treated plasma samples from 52 AD patients in comparison with 52 community-based subjects with normal cognition (NC). The inclusion criterion was proposed by the NINCDS-ADRDA and additionally required at least 6 months of follow-up from the initial clinical diagnosis in the course of AD. Results:The MDS-OAβ values were 1.43±0.30 ng/ml in AD and 0.45±0.19 (p < 0.001) in NC, respectively. Using a cut-off value of 0.78 ng/ml, the results revealed 100% sensitivity and 92.31% specificity. Conclusion:MDS-OAβ to measure plasma Aβ oligomerization is a valuable blood-based biomarker for clinical diagnosis of AD, with high sensitivity and specificity.
